These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15287476)

  • 21. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].
    Bao F; Qu JX; Liu ZJ; Qin XG; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):756-61. PubMed ID: 24433804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.
    Coles CL; Mabula K; Seidman JC; Levens J; Mkocha H; Munoz B; Mfinanga SG; West S
    Clin Infect Dis; 2013 Jun; 56(11):1519-26. PubMed ID: 23487375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.
    Isozumi R; Ito Y; Ishida T; Osawa M; Hirai T; Ito I; Maniwa K; Hayashi M; Kagioka H; Hirabayashi M; Onari K; Tomioka H; Tomii K; Gohma I; Imai S; Takakura S; Iinuma Y; Ichiyama S; Mishima M;
    J Clin Microbiol; 2007 May; 45(5):1440-6. PubMed ID: 17344362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.
    Wierzbowski AK; Karlowsky JA; Adam HJ; Nichol KA; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2014 Jan; 69(1):59-66. PubMed ID: 23970485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase of macrolide-resistant Streptococcus pneumoniae-expressing mefE or ermB gene in the nasopharynx among children with otitis media.
    Hotomi M; Billal DS; Shimada J; Suzumoto M; Yamauchi K; Fujihara K; Yamanaka N
    Laryngoscope; 2005 Feb; 115(2):317-20. PubMed ID: 15689758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital.
    Bonofiglio L; Ojeda MI; de Mier C; Vay C; Famiglietti A; Gutkind G; Mollerach M
    Int J Antimicrob Agents; 2005 Mar; 25(3):260-3. PubMed ID: 15737523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.
    Bojang E; Jafali J; Perreten V; Hart J; Harding-Esch EM; Sillah A; Mabey DC; Holland MJ; Bailey RL; Roca A; Burr SE
    BMC Microbiol; 2017 Mar; 17(1):75. PubMed ID: 28351345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children.
    Chiba N; Kobayashi R; Hasegawa K; Morozumi M; Nakayama E; Tajima T; Iwata S; Ubukata K;
    J Antimicrob Chemother; 2005 Oct; 56(4):756-60. PubMed ID: 16131518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.
    Skalet AH; Cevallos V; Ayele B; Gebre T; Zhou Z; Jorgensen JH; Zerihun M; Habte D; Assefa Y; Emerson PM; Gaynor BD; Porco TC; Lietman TM; Keenan JD
    PLoS Med; 2010 Dec; 7(12):e1000377. PubMed ID: 21179434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.
    Samore MH; Magill MK; Alder SC; Severina E; Morrison-De Boer L; Lyon JL; Carroll K; Leary J; Stone MB; Bradford D; Reading J; Tomasz A; Sande MA
    Pediatrics; 2001 Oct; 108(4):856-65. PubMed ID: 11581436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Streptococcus pneumoniae Serotypes and Antibiotic Susceptibility Patterns in Middle Ear Fluid Isolates During Acute Otitis Media and Nasopharyngeal Isolates During Community-acquired Alveolar Pneumonia in Central Romania.
    Lixandru RI; Falup-Pecurariu C; Bleotu L; Mercas A; Leibovitz E; Dagan R; Greenberg D; Falup-Pecurariu O
    Pediatr Infect Dis J; 2017 Feb; 36(2):151-154. PubMed ID: 27798547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
    File TM; Tan JS
    Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of azithromycin infusion in patients with mild or moderate community-acquired pneumonia].
    Noguchi S; Yatera K; Kawanami T; Yamasaki K; Uchimura K; Hata R; Tachiwada T; Oda K; Hara K; Suzuki Y; Akata K; Ogoshi T; Tokuyama S; Inoue N; Nishida C; Orihashi T; Yoshida Y; Kawanami Y; Taura Y; Ishimoto H; Obata H; Tsuda T; Yoshii C; Mukae H
    Jpn J Antibiot; 2014 Jun; 67(3):193-203. PubMed ID: 25163252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
    Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
    Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation.
    Kays MB; Wack MF; Smith DW; Denys GA
    Diagn Microbiol Infect Dis; 2002 Jun; 43(2):163-5. PubMed ID: 12088625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteremic pneumococcal pneumonia associated with macrolide failure.
    Dylewski J; Davidson R
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):39-42. PubMed ID: 16411124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
    Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
    Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.